drugset / Trial / NCT00131313
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Phase 4
Unknown
180 enrolled
East Valley Hematology and Oncology Medical Group
Astex Pharmaceuticals, Inc. · collabMena, Raul, M.D. · collabPharmatech Oncology · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drugs are being given together for investigational purposes as the specific combination of these three drugs has not been approved for treatment of CLL by the FDA.
Timeline
- Start
- 2003-01
- Primary completion
- —
- Completion
- 2009-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | Pentostatin | Small molecule | — | — |
| Subject | Rituximab | Monoclonal antibody | — | — |